Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001013762-25-001862
Filing Date
2025-03-25
Accepted
2025-03-25 09:00:22
Documents
15
Period of Report
2024-04-01
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 TO FORM 8-K ea0234176-8ka4_aditxt.htm   iXBRL 8-K/A 44959
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF APPILI THERAPEUTICS, IN ea023417601ex99-1_aditxt.htm EX-99.1 227237
3 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION AS OF AND FOR THE TWELVE ea023417601ex99-2_aditxt.htm EX-99.2 282646
  Complete submission text file 0001013762-25-001862.txt   799724

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adtx-20240401.xsd EX-101.SCH 3008
5 XBRL LABEL FILE adtx-20240401_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE adtx-20240401_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0234176-8ka4_aditxt_htm.xml XML 9611
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39336 | Film No.: 25766060
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)